![]() ![]() Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW "Safety and clinical utility of long-term intravenous Milrinone in advanced heart failure." Am J Cardiol 80 (1997): 61-4ģ. Primacor (milrinone)." Sanofi Winthrop Pharmaceuticals (2001):Ģ. Local side effects including infusion site reaction has been reported in postmarketing experience.ġ. Dermatologicĭermatologic side effects including rash has been reported in postmarketing experience. Respiratory side effects have been reported including isolated, spontaneous reports of bronchospasm. Metabolic side effects have included rare reports of hypokalemia (0.6%). Other side effects including rash and skin reactions have been reported in postmarketing experience. Hepatic side effects including liver function test abnormalities have been reported in postmarketing experience. Hypersensitivity reactions including rare instances of bronchospasm and anaphylactic shock have been reported in postmarketing experience. General gastrointestinal complaints have been reported rarely. ![]() The hematologic side effects of milrinone may be important in some patients who are awaiting cardiac catheterization, transplant, or other significant invasive procedures. While these effects have been described in patients undergoing cardiac surgery who had received milrinone for 12 to 24 hours, they have not been associated with acute administration of milrinone. Hematologic side effects of reversible thrombocytopenia (0.4%), inhibition of platelet activity, and increased bleeding time have occurred. Milrinone has been shown to inhibit human platelet thromboxane A2 synthesis and calcium uptake. Dizziness is most often associated with hypotension. Nervous system side effects have included headaches (2.9%) and tremor (0.4%). In addition, rare reports of torsades de pointes have been reported in postmarketing experience. Hypotension (2.9%) and angina/chest pain (1.2%) have occurred. CardiovascularĬardiovascular side effects have included ventricular arrhythmias (12%), ventricular ectopic activity (8%), supraventricular arrhythmias (3.8%), sustained and nonsustained ventricular tachycardia (1% and 2.8%, respectively), ventricular fibrillation (0.2%), and atrial fibrillation. For Healthcare ProfessionalsĪpplies to milrinone: intravenous solution. Ventricular arrhythmias (e.g., ventricular ectopy, nonsustained ventricular tachycardia ), supraventricular arrhythmias, hypotension, headache. For additional information, see the ASHP website. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |